Home › QMSMEDI › Filing
🔔 Get instant alerts when QMSMEDI files quarterly results on BSE Start free trial →

Investor Presentation

Filed: 17 Nov 2026, 11:31 IST Exchange: NSE Category: Financial Results — Investor Presentation
Investor Presentation - Q2 & H1 FY27 - Q2FY27 revenue 52.5 Cr +18% y-y; H1FY27 revenue 109.4 Cr +20% y-y - Consolidation of Patient Support Programs (PSP) and Healthcare Services into Saarathi Healthcare; separate NSE listing planned - Acquisition of BeamOptics Scientific to expand diagnostics and product innovation capabilities - PSP business targets double-digit market share in a 10,000-12,000 Cr pharma spend market - FY26 consolidated revenue 173 Cr, EBITDA margin 15%, PAT margin 6.9% - Management aims for margin expansion and market leadership post integration - Strong pan-India presence with 2000+ professionals, 35+ cities coverage - Proprietary digital health platform supports 1M+ patients and 160+ active programs
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 QMSMEDI — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add QMSMEDI to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on QMS Medical Allied Services Limited

Important. The summary above is generated automatically from QMS Medical Allied Services Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.